Corrigendum: RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features (Leukemia (2016) 30 (2160-2168) DOI: 10.1038/leu.2016.126);RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

Leukemia

Volumn 30, Issue 11, 2016, Pages 2160-2168

  Gaidzik, V I ^a   Teleanu, V ^a   Papaemmanuil, E ^b   Weber, D ^a   Paschka, P ^a   Hahn, J ^a   Wallrabenstein, T ^a   Kolbinger, B ^a   Kohne C H ^c   Horst, H A ^d   Brossart, P ^e   Held, G ^f   Kundgen A ^g   Ringhoffer, M ^h   Gotze K ⁱ   Rummel, M ^j   Gerstung, M ^b   Campbell, P ^b   Kraus, J M ^k   Kestler, H A ^k   Thol, F ^l   Heuser, M ^l   Schlegelberger, B ^l   Ganser, A ^l   Bullinger, L ^a   Schlenk, R F ^a   Dohner K ^a   Dohner H ^a   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c KLINIKUM OLDENBURG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL GIESSEN   (Germany)

^k UNIVERSITY OF ULM   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LACTATE DEHYDROGENASE; NUCLEOPHOSMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; RUNX1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASXL1 GENE; BCOR GENE; CANCER PROGNOSIS; CANCER SURVIVAL; DE NOVO ACUTE MYELOID LEUKEMIA; EPIGENETICS; EVENT FREE SURVIVAL; EXON; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; KMT2A GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHF6 GENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SECONDARY ACUTE MYELOID LEUKEMIA; SEX DIFFERENCE; SF3B1 GENE; SPLICEOSOME; SRSF2 GENE; STAG2 GENE; TREATMENT RESPONSE; ACUTE MYELOID LEUKEMIA; AGE; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; AGE FACTORS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; EPIGENOMICS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SEX FACTORS; SPLICEOSOMES; SURVIVAL RATE; YOUNG ADULT;

EID: 84973659562     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.207     Document Type: Erratum

References (55)

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136-1152.
2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.
4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit et al. The 2008 revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: rationale and important changes. Blood 2009; 114: 937-951.
5. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
6. Döhner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program 2011; 2011: 36-42.
7. Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol 2014; 15: e382-e394.
8. Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood 2015; 125: 767-774.
9. Okuda T, van Deuersen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
10. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10: 299-304.
11. Mangan JK, Speck NA. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 2011; 16: 77-91.
12. Sakurai M, Kunimoto H, Watanabe N, Fukuchi Y, Yuasa S, Yamazaki S et al. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients. Leukemia 2014; 28: 2344-2354.
13. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999; 93: 1817-1824.
14. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 2000; 96: 3154-3160.
15. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL et al. High incidence of biallelic point mutations in the Runt domain of the AML1/ PEBP2 alpha B gene in M0 acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 2000; 96: 2862-2869.
16. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC et al. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405-414.
17. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308-1316.
18. Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008; 8: 299.
19. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114: 5352-5361.
20. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W et al. Mutation analysis for RUNX1, KMT2A-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 1528-1532.
21. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29: 1364-1372.
22. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117: 2348-2357.
23. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
24. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 2012; 30: 3109-3118.
25. Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica 2012; 97: 1909-1915.
26. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
27. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
28. Grossmann V, Kern W, Harbich S, Alpermann T, Jeromin S, Schnittger S et al. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica 2011; 96: 1874-1877.
29. Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74: 47-53.
30. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101: 673-680.
31. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004; 104: 1474-1481.
32. Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pagès MP et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011; 117: e161-e170.
33. Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: A unique pathway in myeloid leukemogenesis. Blood 2014; 123: 2229-2237.
34. Jongmans MC, Kuiper RP, Carmichael CL, Wilkins EJ, Dors N, Carmagnac et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia 2010; 24: 242-246.
35. Owen C. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML). Leuk Res 2010; 34: 141-142.
36. Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009; 113: 5583-5587.
37. Nickels EM, Soddalter J, Churpek JE, Godley LA. Recognizing familial myeloid leukemia in adults. Ther Adv Hematol 2013; 4: 254-269.
38. Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28: 4642-4648.
39. Schlenk RF, Döhner K, Krauter J, Gaidzik V, Paschka P, Heuser M et al. All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia-results of the AMLSG 07-04 randomized treatment trial [abstract]. Haematologica 2014; 99, abstract 646.
40. Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798-1803.
41. Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 2014; 123: 4027-4036.
42. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
43. Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013; 121: 4769-4777.
44. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643.
45. Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L et al. ASXL1 mutations are associated with distinct clinical and genetic features and confer poor prognosis in younger adult patients with acute myeloid leukemia: A study of the German-Austrian AML Study Group. Haematologica 2015; 100: 324-330.
46. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986; 5: 255-260.
47. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
48. Therneau TM, Grambusch PM. Modeling Survival Data: Extending the Cox Model. Springer Verlag: New York, NY, USA, 2000.
49. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
50. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367: 1355-1360.
51. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer Verlag: New York, NY, USA, 2001.
52. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2009.
53. Chvatal V. A greedy heuristic for the set-covering problem. Math Oper Res 1979; 4: 233-235.
54. Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M. Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 2012; 119: 3890-3899.
55. Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 2014; 124: 1790-1798.